Candel Therapeutics 公布局部前列腺癌药物 Aglatimagene Besadenovec (Can-2409) 三期试验长期随访数据,显示多临床终点持续获益

美股速递
May 16

在2026年美国泌尿外科协会年会上,Candel Therapeutics 公布了其针对局部前列腺癌的候选药物 Aglatimagene Besadenovec (Can-2409) 三期临床试验的长期随访数据。数据显示,经过延长随访期,该疗法在多个关键临床终点上持续为患者带来显著的临床获益。

此次公布的数据进一步证实了 Can-2409 在治疗局部前列腺癌患者中的持久疗效与安全性。长期跟踪结果凸显了该疗法在延缓疾病进展、改善患者生活质量等核心指标上的积极作用,为这一创新疗法的潜在价值提供了有力支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10